Cutaneous melanoma (SKCM)是最危险的皮肤癌，缺乏早期检测和有效的治疗策略。许多长链非编码RNA与肿瘤的发展有关，可能成为潜在的免疫治疗靶点。本研究采用微阵列分析筛选SKCM和正常组织之间差异表达的lncRNAs，鉴定SMG7-AS1为SKCM中的上调lncRNA。随之进行的生物信息学分析揭示SMG7-AS1调控转移和免疫细胞浸润的失调。临床样本的qRT-PCR显示SMG7-AS1在黑色素瘤组织中的表达水平更高。流式细胞术显示SMG7-AS1在细胞周期中发挥着重要作用。此外，SMG7-AS1与免疫治疗反应有关。据我们所知，本研究首次报告SMG7-AS1与SKCM的相关性，可能成为SKCM的预后生物标志物和免疫治疗反应预测因子。版权所有 © 2023 Elsevier Inc.发布。

Skin cutaneous melanoma (SKCM) is the most life-threatening skin cancer and lacks early detection and effective treatment strategies. Many long noncoding RNAs are associated with the development of tumors and may serve as potential immunotherapeutic targets. In this study, microarray analysis was performed to screen for differentially expressed lncRNAs between SKCM and normal tissues, and SMG7-AS1 was identified as an upregulated lncRNA in SKCM. Subsequently, bioinformatic analysis revealed that dysregulation of SMG7-AS1 influences metastasis and immune infiltration. qRT-PCR of clinical samples demonstrated that the expression of SMG7-AS1 was higher in melanoma tissues. Flow cytometry showed that SMG7-AS1 plays a vital role in the cell cycle. Additionally, SMG7-AS1 was found to be associated with immunotherapy responses. To the best of our knowledge, this study is the first to report that SMG7-AS1 is associated with SKCM and may serve as a prognostic biomarker and predictor of immunotherapy responses in SKCM.Copyright © 2023. Published by Elsevier Inc.